Benitec Biopharma Inc.
BNTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001808898
No open-market purchases or sales by Benitec Biopharma Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $443.3M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Benitec Biopharma Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +7 vs. Q2 2024
- Shares held
- 13.7M
- +7.39M (+116.8%) vs. Q2 2024
- Total value
- $126.8M
- +$82.7M (+187.4%) vs. Q2 2024
- New holders
- 7
- 5 more added
- Sold out
- 0
- 8 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BNTC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 86 | $443.3M |
| Q1 2026 | 88 | $346.0M |
| Q4 2025 | 72 | $426.6M |
| Q3 2025 | 56 | $324.7M |
| Q2 2025 | 57 | $265.3M |
| Q1 2025 | 37 | $290.1M |
| Q4 2024 | 30 | $240.2M |
| Q3 2024 | 25 | $126.8M |
| Q2 2024 | 19 | $44.3M |
| Q1 2024 | 13 | $6.58M |
| Q4 2023 | 13 | $3.88M |
| Q3 2023 | 12 | $3.84M |
| Q2 2023 | 17 | $2.45M |
| Q1 2023 | 21 | $2.44M |
| Q4 2022 | 25 | $2.09M |
| Q3 2022 | 25 | $5.92M |
| Q2 2022 | 22 | $1.55M |
| Q1 2022 | 21 | $2.60M |
| Q4 2021 | 17 | $4.16M |
| Q3 2021 | 19 | $5.43M |
| Q2 2021 | 18 | $6.46M |
| Q1 2021 | 15 | $1.84M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Benitec Biopharma Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 68 | $625 | 0.00% | −9−11.7% | Reduced |
| Group One Trading, L.P. | 89 | $818 | 0.00% | 00.0% | Unchanged |
| Rhumbline Advisers | 186 | $1.71K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 230 | $2.11K | 0.00% | −661−74.2% | Reduced |
| GWM Advisors LLC | 610 | $5.61K | 0.00% | +610 | New |
| Morgan Stanley | 1,324 | $12.2K | 0.00% | −4,276−76.4% | Reduced |
| UBS Group AG | 1,924 | $17.7K | 0.00% | −108−5.3% | Reduced |
| GAMMA Investing LLC | 6,540 | $60.1K | 0.01% | +1,102+20.3% | Added |
| Citadel Advisors LLC | 14,244 | $130.9K | 0.00% | +14,244 | New |
| Ameriprise Financial Inc | 14,879 | $136.7K | 0.00% | +14,879 | New |
| Northern Trust Corp | 24,775 | $227.7K | 0.00% | −149−0.6% | Reduced |
| BlackRock, Inc. | 28,238 | $259.5K | 0.00% | +28,238 | New |
| Acuta Capital Partners, LLC | 29,800 | $273.9K | 0.22% | +29,800 | New |
| Lion Point Capital, LP | 39,000 | $358.4K | 1.44% | +39,000 | New |
| Armistice Capital, LLC | 60,000 | $551.4K | 0.01% | +60,000 | New |
| Geode Capital Management, LLC | 83,987 | $772.1K | 0.00% | +20,012+31.3% | Added |
| Simplify Asset Management Inc. | 116,535 | $1.07M | 0.07% | +65,319+127.5% | Added |
| Vanguard Group Inc | 213,067 | $1.96M | 0.00% | −2,003−0.9% | Reduced |
| Schonfeld Strategic Advisors LLC | 272,817 | $2.51M | 0.02% | +12,400+4.8% | Added |
| AWM Investment Company, Inc. | 625,000 | $5.74M | 0.70% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 838,095 | $7.70M | 0.65% | −3,300−0.4% | Reduced |
| Adage Capital Partners GP, L.L.C. | 841,395 | $7.73M | 0.01% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 876,523 | $8.03M | 0.00% | −24,293−2.7% | Reduced |
| Franklin Resources Inc | 796,644 | $8.09M | 0.00% | 00.0% | Unchanged |
| Suvretta Capital Management, LLC | 8,829,053 | $81.1M | 2.91% | +7,137,763+422.0% | Added |
| BlackRock Inc. | – | – | – | – | Not filed |